Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11514704 | 0.89 | OPRD1 (0.47) | OPRD1OPRM1CTSLMMEACE | |
| SCHEMBL10756316 | 0.88 | TSHR (0.46) | OPRD1OPRM1CTSLMMEACE | |
| SCHEMBL10758438 | 0.86 | OPRD1 (0.56) | OPRD1OPRM1MMEACECPA1 | |
| SCHEMBL10756817 | 0.86 | OPRD1 (0.56) | OPRD1OPRM1MMEACECPA1 | |
| SCHEMBL30578441 | 0.84 | OPRD1 (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29440279 | 0.81 | OPRD1 (0.54) | OPRD1OPRM1CTSLOPRK1CTSS | |
| SCHEMBL9724062 | 0.80 | GRIA1 (0.59) | OPRD1OPRM1CTSLACECPA1 | |
| SCHEMBL21415384 | 0.80 | GRIA1 (0.46) | OPRD1OPRM1CTSLOPRK1CTSS | |
| SCHEMBL16217709 | 0.80 | GRIA1 (0.46) | OPRD1OPRM1CTSLOPRK1CTSS | |
| SCHEMBL16656679 | 0.80 | GRIA1 (0.46) | OPRD1OPRM1CTSLOPRK1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969773-B2 | Polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (US) | 2018-05-15 | — | — | US | disclosed |
| US-20150299254-A1 | NOVEL POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | NEW YORK UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299254-A1 | NOVEL POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | PAICS, F12, CYP2C19 | OPRD1 803/4885OPRM1 1158/4885CTSL 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.